Tango Therapeutics (TNGX) Liabilities and Shareholders Equity (2020 - 2026)

Tango Therapeutics' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $435.8 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 58.87% year-over-year to $435.8 million; the TTM figure through Mar 2026 stood at $1.3 billion (down 3.18% YoY), while the FY2025 annual figure was $398.7 million, up 25.97% from the prior year.
• Liabilities and Shareholders Equity was $435.8 million for Q1 2026 at Tango Therapeutics, up from $398.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $471.5 million in Q1 2022 to a low of $210.1 million in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $379.3 million across 5 years, with a median of $402.6 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity surged 180.23% in 2022, then plunged 40.37% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $436.5 million in 2022, then retreated by 7.77% to $402.6 million in 2023, then fell by 21.38% to $316.5 million in 2024, then gained by 25.97% to $398.7 million in 2025, then climbed by 9.31% to $435.8 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $435.8 million (Q1 2026), $398.7 million (Q4 2025), and $210.1 million (Q3 2025), per Business Quant data.